{"id":"NCT02002884","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy","officialTitle":"Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses XeominÂ® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-28","primaryCompletion":"2017-07-04","completion":"2018-08-28","firstPosted":"2013-12-06","resultsPosted":"2020-08-03","lastUpdate":"2021-08-05"},"enrollment":351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cerebral Palsy","Spasticity"],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (8 Units per kg body weight)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"IncobotulinumtoxinA (6 Units per kg body weight)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"IncobotulinumtoxinA (2 Units per kg body weight)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]}],"arms":[{"label":"8 Units per kg body weight incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"},{"label":"6 Units per kg body weight incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"},{"label":"2 Units per kg body weight incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.","primaryOutcome":{"measure":"MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4","timeFrame":"Baseline and Week 4","effectByArm":[{"arm":"MP Low Dose Group","deltaMin":-0.93,"sd":0.078},{"arm":"MP High Dose Group","deltaMin":-1.15,"sd":0.056}],"pValues":[{"comp":"OG000 vs OG002","p":"= 0.017"},{"comp":"OG000 vs OG001","p":"= 0.546"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States","Argentina","Mexico","Poland","Russia","Ukraine"]},"refs":{"pmids":["34339951","36136523"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":87},"commonTop":["Nasopharyngitis"]}}